Moonlight AI provides an AI diagnostics platform that democratizes access to genomic information for personalized medicine in hematologic cancers. The platform uses computer vision to identify genomic aberrations directly from blood or bone marrow smears, significantly reducing the time and cost of traditional Next-Generation Sequencing (NGS) testing. This enables faster diagnosis, response assessment, and continuous treatment optimization for individual cancer patients.
Funding
$380K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Hematologic cancers affect millions globally, and precision medicine requires genomic information to match patients with targeted therapies. However, access to genomic information is limited by the high cost and complexity of Next-Generation Sequencing (NGS) and the need for specialized instruments. This creates delays and disparities in treatment decisions for cancer patients.
Solution
Moonlight AI offers an AI-powered diagnostics platform that analyzes blood or bone marrow smears using computer vision to identify genomic aberrations. This approach provides faster and more affordable genomic insights compared to traditional NGS methods, enabling hematologists to make informed treatment decisions more rapidly. The platform facilitates not only faster and more affordable initial diagnoses but also enables continuous response assessment and relapse detection. By democratizing access to genomic information, Moonlight AI aims to improve treatment outcomes for cancer patients.
Target Audience
The primary users are hematologists and oncologists who require rapid and cost-effective genomic information for making treatment decisions for cancer patients.
Features
- AI-based models for identifying genomic aberrations directly from blood or bone marrow smears
- Computer vision algorithms for analyzing cellular morphology and detecting genetic mutations
- Rapid turnaround time compared to traditional Next-Generation Sequencing (NGS)
- Enables faster and more affordable diagnosis of hematologic cancers
- Facilitates continuous response assessment and relapse detection